Hi-Tech Pharmacal competitors

Joe Ciaffoni was appointed President and Chief Executive Officer of Collegium Pharmaceutical in July 2018. Joe Ciaffoni joined Collegium Pharmaceutical in May 2017 as Executive Vice President and Chief Operating Officer. Prior to joining Collegium, he served as President, U.S. Branded Pharmaceuticals of Endo International plc. Before that, Joe Ciaffoni held various positions of increasing responsibility at Biogen, including Senior Vice President, Global Specialty Medicines Group, Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen, he was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Joe Ciaffoni also previously served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Joe Ciaffoni received a B.A. in Communications and an M.B.A. from Rutgers.

James E. Brown, D.V.M. co-founded DURECT in February 1998 and has served as President, Chief Executive Officer and a Director since June 1998. He previously worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development from June 1995 to June 1998. Prior to that, Dr. Brown held various positions at Syntex Corporation, a pharmaceutical company, including Director of Business Development from May 1994 to May 1995, Director of Joint Ventures for Discovery Research from April 1992 to May 1995, and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992. Dr. Brown holds a B.A. from San Jose State University and a D.V.M. (Doctor of Veterinary Medicine) from the University of California, Davis where he also conducted post-graduate work in pharmacology and toxicology.

Emil Kakkis (born 1960) is an American medical geneticist known for his work to develop treatments for ultra rare disorders. He is the President and Founder of the Kakkis Everylife Foundation for Rare Disease and Chief Executive Officer and President at Ultragenyx Pharmaceutical Inc.

Stephan Kutzer is a Chief Executive Officer at CAMBRIDGE MAJOR LABORATORIES and Chief Executive Officer at AAIPharma Services. He has worked as COO:Pharma & Biotech Mkt Segment at Lonza America Inc., Head:Performance Chemicals at Lonza America Inc., and Assistant Production Manager at Lonza America Inc.. Stephan attended Technical University of Munich.

Mr. Patel’s lifelong drive and constant desire to discover what’s next has carried Amneal Pharmaceuticals from humble beginnings to an emerging global presence. Patel is the recipient of several industry honors including the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award® and supports various philanthropic and charitable causes both in the US and abroad. Patel and his wife, Priti Patel, established the Niswarth Children Foundation in 2013, with the goal of bringing fresh water, sanitation, sustenance, and education to one million underprivileged children. Patel received his bachelor’s degree in commerce from H.A. College of Commerce, India, and his Bachelor of Science in business administration from New Jersey City University. He also received an honorary degree of doctor of humane letters from New Jersey City University in recognition of his efforts to serve others and help them transform their lives. Patel serves on the boards of the Generic Pharmaceutical Association, the Art of Living Foundation, the New Jersey City University Foundation, and the Family Reach Foundation.

Anil D'souza is a Chief Executive Officer at TOLMAR and is based in Lincolnshire, Illinois. He has worked as President, Japan & Emerging Markets at HOSPIRA INC; First Lieutenant at Marine Corps Recruiting; and Client Manager at INTERNATIONAL BUSINESS MACHINES CORP. Anil attended Tuck School of Business at Dartmouth between 1998 and 2000, University of Chicago Committee on International Relations between 1989 and 1991, and University of Chicago between 1987 and 1991.

Cameron Reid is a Board Member at CHEMINOR DRUGS LIMITED and Chief Executive Officer at Interpharm Holdings Inc. He has worked as President at DR. REDDY'S LABORATORIES and Board Member at Interpharm Holdings Inc. Cameron works or has worked as Executive Vice President at Roussel NV. He studied at UCalgary and INSEAD.

Ian Lennox is a CEO/Chairman at Olon Ricerca Bioscience LLC. He attended HBSc and MBA.